All In Biotech

Drug Trial Radar · NCT07222189

A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

A Multinational, Multicenter Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Adults With Crohn's Disease or Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

7

Actual

Start

May 19, 2026

Primary completion

Sep 29, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 77 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively. * The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period. * The study will consist of 2 independent cohorts through the study given the distinct nature of each disease: * CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212). * UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822). * The study will consist of the following study periods for each cohort: * A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies. * An Open-Label (OL) treatment period of up to 104 weeks for: * Eligible participants from either the DB or OL periods of the parent studies, * Eligible participants who meet escape criteria at any time during the DB period of the LTS19689. * A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.

Conditions

  • Colitis Ulcerative
  • Crohn's Disease

Interventions

  • balinatunfibDrug

    Pharmaceutical form:Tablet -Route of administration:Oral

  • balinatunfib-matching placeboDrug

    Pharmaceutical form:Tablet -Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to End of Study (approximately 106 weeks)
  2. Number of participants with ulcerative colitis with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to End of Study (approximately 106 weeks)

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400005

    Southlake, Texas

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 1000001

    Gorna Oryahovitsa, Bulgaria

  • Investigational Site Number : 1520016

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520010

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520012

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1560002

    Guangzhou, China

  • Investigational Site Number : 1560032

    Shanghai, China

  • Investigational Site Number : 2030001

    Olomouc, Czechia

  • Investigational Site Number : 3800002

    Milan, Milano, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.